ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics (ITI), pioneering the study of investigational LAMP-based nucleic acid immunotherapy programs, announced today that the company will participate at the 2018 BIO CEO & Investor Conference in two events:
Monday, February 12, 2018, 7-9 p.m. EST, New York Marriott Marquis, Manhattan Ballroom
Scientific American Panel: “Hot Topics in Biotech: Cancer at a
As new financing models become increasingly complex, immuno-oncology technologies present a promising, but complex landscape. Scientific American is hosting a salon conversation with leading industry experts like ITI focused on immuno-oncology.
- William Hearl, Ph.D., Founder & CEO, ITI
- Jeremy Abbate, VP & Publisher, Scientific American
- Andrew Marshall, Chief Editor, Nature Biotech
- Barbara Ryan, Life Sciences Capital Markets & Strategy Advisor, Financial Communications, CNBC
- Cliff Ransom, Executive Editor, Scientific American
Tuesday, February 13, 2018, 2:45 p.m. EST, Gilbert Room, New York Marriott Marquis
- Corporate presentation: ITI’s Founder & CEO, William Hearl, Ph.D., will present an overview of the company and its LAMP-Vax technology.
ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP Technology, visit www.immunomix.com.